As Allergan stock continues to languish, two large hedge funds wrote a blistering letter to the drug maker’s board, urging them to split the roles of chairman and chief executive into separate positions, overhaul top management, and abandon an acquisition strategy.

In harsh language, Appaloosa Management and Senator Investment Group criticized Allergan chief executive Brent Saunders and his board for “token measures” to revive the stock. Allergan shares are down about 33 percent in the past 12 months, although the stock was up nearly 1 percent at midday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy